PSMA-11 free base

  • CAT Number: I035163
  • CAS Number: 1366302-52-4
  • Molecular Formula: C44H62N6O17
  • Molecular Weight: 947.005
  • Purity: 98%
Inquiry Now

PSMA-11 free base(CAT: I035163), also known as DKFZ-PSMA-11 or HBED-CC-PSMA, is a ligand used for gallium Ga 68-labeled PSMA-11, a radiotracer for PET imaging of PSMA-expressing tumors. PSMA-11 targets PSMA, a membrane protein expressed on prostatic epithelial and prostate tumor cells. Upon intravenous administration of the radiotracer, PSMA-expressing tumor cells can be detected during PET imaging. PSMA-11 enables the diagnosis, staging, and monitoring of prostate cancer due to its high specificity for PSMA-expressing cells.

Catalog Number I035163
CAS Number 1366302-52-4
Synonyms

DKFZ-​PSMA-​11; Psma-hbed-CC; PSMA-11; PSMA11; PSMA 11; HBED-CC-PSMA; PSMA-11 TFA; Psma-hbed-CC

Molecular Formula

C44H62N6O17

Purity 98
Solubility To be determined
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name (3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid
InChI InChI=1S/C44H62N6O17/c51-34-13-8-28(22-30(34)24-49(26-40(59)60)20-21-50(27-41(61)62)25-31-23-29(9-14-35(31)52)11-16-38(55)56)10-15-37(54)46-18-4-1-2-7-36(53)45-19-5-3-6-32(42(63)64)47-44(67)48-33(43(65)66)12-17-39(57)58/h8-9,13-14,22-23,32-33,51-52H,1-7,10-12,15-21,24-27H2,(H,45,53)(H,46,54)(H,55,56)(H,57,58)(H,59,60)(H,61,62)(H,63,64)(H,65,66)(H2,47,48,67)/t32-,33-/m0/s1
InChIKey QJUIUFGOTBRHKP-LQJZCPKCSA-N
SMILES O=C(O)CC[C@H](NC(N[C@@H](CCCCNC(CCCCCNC(CCC1=CC=C(O)C(CN(CC(O)=O)CCN(CC2=CC(CCC(O)=O)=CC=C2O)CC(O)=O)=C1)=O)=O)C(O)=O)=O)C(O)=O
Reference

1: Verma P, Malhotra G, Meshram V, Chandak A, Sonavane S, Lila AR, Bandgar TR, Asopa RV. Prostate-Specific Membrane Antigen Expression in Patients With Differentiated Thyroid Cancer With Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl Med. 2021 Aug 1;46(8):e406-e409. doi: 10.1097/RLU.0000000000003655. PMID: 33883490.
2: Guglielmo P, Gasparro D, Scarlattei M, Baldari G, Bola S, Migliari S, Sammartano A, Maestroni U, Ruffini L. [68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2021 Mar 22. doi: 10.1007/s00259-021-05250-1. Epub ahead of print. PMID: 33754194.
3: Malhotra G, Aute PP, Awasare S, Asopa RV. 68Ga-PSMA-HBED-CC PET/CT Findings in a Patient of Polyostotic Fibrous Dysplasia. Clin Nucl Med. 2021 Jul 1;46(7):e349-e352. doi: 10.1097/RLU.0000000000003492. PMID: 33417342.
4: Yip JWL, Hilliar L, Le K, Loh H, Mansberg R. 68Ga-Prostate-Specific Membrane Antigen Solitary Base of Skull Prostate Adenocarcinoma Metastasis. Clin Nucl Med. 2021 Jan;46(1):63-65. doi: 10.1097/RLU.0000000000003390. PMID: 33181755.
5: Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, Shariat SF, Rasul S. Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI). Prostate Cancer Prostatic Dis. 2021 Jun;24(2):439-447. doi: 10.1038/s41391-020-00294-0. Epub 2020 Sep 29. PMID: 32994534.
6: Golan H, Esa M, Moshkoviz K, Feldhaim A, Hoch B, Shalom E. Enhancing capacity and synthesis of [68Ga]68-Ga-PSMA-HBED-CC with the lyophilized ready-to-use kit for nuclear pharmacy applications. Nucl Med Commun. 2020 Sep;41(9):986-990. doi: 10.1097/MNM.0000000000001232. PMID: 32796488.
7: Sørensen MA, Andersen VL, Hendel HW, Vriamont C, Warnier C, Masset J, Huynh THV. Automated synthesis of 68 Ga/177 Lu-PSMA on the Trasis miniAllinOne. J Labelled Comp Radiopharm. 2020 Jun 30;63(8):393-403. doi: 10.1002/jlcr.3846. Epub 2020 Jun 1. PMID: 32374450.
8: Wong VCK, Yip JWL, Stevanovic A, Le K, Mansberg R. 68Ga-Prostate-Specific Membrane Antigen Uptake in Dissecting Abdominal Aortic Aneurysm. Clin Nucl Med. 2020 Jun;45(6):455-458. doi: 10.1097/RLU.0000000000002972. PMID: 32149812.
9: Sood A, Vadi SK, Kumar R, Singh H, Mittal BR. Incidental Detection of Hypothyroidism on 68Ga-PSMA-HBED-CC PET/CT Imaging. Clin Nucl Med. 2020 Apr;45(4):e217-e218. doi: 10.1097/RLU.0000000000002965. PMID: 32108699.
10: van Boxtel W, Lütje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, Nagarajah J, Gotthardt M, van Herpen CML. 68Ga-PSMA-HBED- CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020 Jan 12;10(5):2273-2283. doi: 10.7150/thno.38501. PMID: 32089741; PMCID: PMC7019174.
11: Sakthivel P, Thakar A, Prashanth A, Bhalla AS, Kakkar A, Sikka K, Singh CA, Kumar R, Sharma SC, Kumar R. Prostate-Specific Membrane Antigen Expression in Primary Juvenile Nasal Angiofibroma-A Pilot Study. Clin Nucl Med. 2020 Mar;45(3):195-199. doi: 10.1097/RLU.0000000000002928. PMID: 31977481.
12: Wong VCK, Shen L, Nasser E, Adams DN, Mansberg R. 68Ga-Prostate-Specific Membrane Antigen Uptake in Cerebral Tuberculosis. Clin Nucl Med. 2020 Mar;45(3):238-240. doi: 10.1097/RLU.0000000000002910. PMID: 31977467.
13: Pollard JH, Raman C, Zakharia Y, Tracy CR, Nepple KG, Ginader T, Breheny P, Sunderland JJ. Quantitative Test-Retest Measurement of 68Ga-PSMA- HBED-CC in Tumor and Normal Tissue. J Nucl Med. 2020 Aug;61(8):1145-1152. doi: 10.2967/jnumed.119.236083. Epub 2019 Dec 5. PMID: 31806776.
14: Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, Seth A. Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration- Resistant Prostate Cancer Patients. Clin Nucl Med. 2020 Jan;45(1):19-31. doi: 10.1097/RLU.0000000000002833. PMID: 31789908.
15: Parihar AS, Sood A, Mittal BR, Kumar R, Singh H, Dhatt SS. 68Ga-PSMA-HBED-CC PET/CT and 18F-FDG PET/CT in Ewing Sarcoma. Clin Nucl Med. 2020 Jan;45(1):e57-e58. doi: 10.1097/RLU.0000000000002764. PMID: 31524682.
16: Schmidkonz C, Cordes M, Goetz TI, Prante O, Kuwert T, Ritt P, Uder M, Wullich B, Goebell P, Bäuerle T. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients. Ann Nucl Med. 2019 Oct;33(10):766-775. doi: 10.1007/s12149-019-01387-0. Epub 2019 Jul 23. PMID: 31338731.
17: Wo S, Matesan MC. 18F-Fluciclovine Uptake in Celiac Ganglia: A Pitfall in Prostate Cancer PET Imaging. Clin Nucl Med. 2019 Sep;44(9):743-745. doi: 10.1097/RLU.0000000000002693. PMID: 31283598.
18: Sheng K, Le K, Bui C, Mansberg R. Incidental Detection of Splenic Hemangioma on 68Ga-PSMA PET/CT. Clin Nucl Med. 2019 Oct;44(10):821-823. doi: 10.1097/RLU.0000000000002662. PMID: 31162264.
19: McCarthy M, Francis R, Tang C, Watts J, Campbell A. A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging. Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):801-808. doi: 10.1016/j.ijrobp.2019.03.014. Epub 2019 Mar 16. PMID: 30890448.
20: Verma P, Malhotra G, Goel A, Rakshit S, Chandak A, Chedda R, Banerjee S, Asopa RV. Differential Uptake of 68Ga-PSMA-HBED-CC (PSMA-11) in Low-Grade Versus High-Grade Gliomas in Treatment-Naive Patients. Clin Nucl Med. 2019 May;44(5):e318-e322. doi: 10.1097/RLU.0000000000002520. PMID: 30829867.

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!